SOURCE: CLX Medical, Inc.

September 15, 2008 13:40 ET

CLX Medical, Inc. Announces Form 4 Filings by Board of Directors

MURRIETA, CA--(Marketwire - September 15, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced Form 4 filings by the company's Board of Directors.

On September 12, 2008, Directors Robert McCoy, Patrick Edgerton and James Bickel each filed a Form 4 Statement of Change in Beneficial Ownership of Securities with the Securities and Exchange Commission. The stock acquired by each of the Directors was granted by the company dating back as far as January 2007 as part of their respective compensation packages.

A link to the company's SEC filings can be found in the "Corporate" section of the CLX Medical website, www.clxmedical.com.

"The service of CLX Medical's Board of Directors has been integral to the effective execution of the company's business strategy, especially as it relates to the expected acquisition of ThyroTest®," commented CLX Medical CEO Vera Leonard. "We are pleased that the Board has expressed confidence in the company and is vested in its long term success by receiving restricted common stock as part of their compensation packages."

CLX Medical has entered into a letter of intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. The company expects to announce a definitive agreement for the acquisition of ThyroTest®, which would be positioned in a wholly owned subsidiary of CLX Medical, very shortly.

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for Chlamydia. CLX recently announced a letter of intent to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    951-677-8073
    Email Contact